Collagen and Menopause: What Happens to Your Body and What the Research Shows
Share
During the first five years after menopause, women can lose up to 30% of their skin collagen. That figure alone does not capture the full picture. The same oestrogen decline that accelerates skin ageing also affects bone density, joint cartilage, hair thickness and connective tissue throughout the body. Here is what the research shows.
Menopause is a hormonal transition, but its effects are structural. Oestrogen is not just a reproductive hormone. It is a key regulator of collagen synthesis throughout the body, stimulating the fibroblasts that produce collagen and slowing the enzymatic processes that break it down. When oestrogen levels fall, both of those mechanisms shift simultaneously — production slows and breakdown accelerates.
The result is a net decline in collagen that affects multiple tissues at once. The skin thins and loses elasticity. Joint cartilage becomes less resilient. Bone density falls. Hair follicles produce thinner, more fragile strands. These are not separate and unrelated symptoms of ageing. They are the downstream consequences of a single biological change playing out across the body's connective tissue systems.
Understanding that connection changes how you think about what nutritional support can and cannot do during this period of life.
Why oestrogen and collagen are so closely linked
Oestrogen receptors are found on fibroblasts, the cells responsible for producing collagen in the skin, tendons, ligaments and other connective tissues. When oestrogen binds to these receptors, it upregulates collagen synthesis and suppresses the activity of matrix metalloproteinases, the enzymes that break collagen fibres down.
This is why the menopause transition creates such an abrupt change. It is not a gradual drift in collagen status. During the first five years of menopause, women lose about 30% of their collagen, followed by an annual decline of approximately 2.1% over the next 15 years. That front-loaded loss in the early post-menopausal years reflects the sudden withdrawal of oestrogen's protective effect on collagen-producing cells.
What makes this clinically important is that the same rate of collagen decline that shows up in skin also shows up in bone. There is evidence that skin collagen content and bone mass are influenced by oestrogen deficiency, both of them declining in the years following menopause. This parallel decline is not coincidental. The same fibroblast and osteoblast signalling pathways that oestrogen regulates in skin are operating in bone matrix as well.
How menopause affects each tissue system
Skin
The decline in oestrogen during menopause contributes to structural and functional skin changes, including decreased collagen production, reduced elasticity, and moisture loss, resulting in dryness and wrinkling. These changes are most rapid in the perimenopause and early post-menopause period, which is also when women are most likely to notice a visible shift in how their skin looks and feels.
The research on collagen supplementation for skin is the most mature of any of the tissue areas. A 2019 meta-analysis of 11 randomised controlled trials involving over 800 participants found that oral collagen peptides improved skin elasticity, hydration, and dermal collagen density compared with placebo. Some studies specifically in postmenopausal women show modest improvements in wrinkle depth and skin thickness after 8 to 12 weeks of daily supplementation.
A 2025 randomised controlled study in menopausal women found that six-month supplementation with collagen peptides, particularly when combined with calcium and vitamin D, improves skin hydration and elasticity in menopausal women, with the collagen group showing improved elasticity of 12.23% compared to baseline.
Hair
Hair thinning is one of the most distressing symptoms of the menopause transition and one of the least discussed. It is not always caused by the same mechanism as androgenic alopecia. In many women, the primary driver is the loss of oestrogen's stimulatory effect on hair follicle cells and the reduced availability of the proline and glycine that form keratin, the primary protein in hair.
The 2025 RCT in menopausal women mentioned above also found that collagen-supplemented groups significantly retarded hair shedding compared to the placebo group. This aligns with in vitro research showing that specific collagen peptides can directly stimulate hair follicle cell proliferation — a mechanism relevant to the follicle miniaturisation that accompanies oestrogen withdrawal.
Joints
Menopausal women often report increased joint pain and stiffness, which can be attributed to the thinning of cartilage. Collagen degradation reduces the ability of cartilage to absorb shock and maintain smooth joint movement. This is particularly common in the knees, hips, fingers and spine, and is often misattributed to general ageing rather than recognised as a hormonally mediated collagen change.
Articular cartilage is approximately 70% collagen by dry weight. It has no blood supply and cannot repair itself through the inflammatory pathways available to other tissues. Its maintenance depends entirely on the activity of chondroblasts — cells that are themselves sensitive to the collagen substrate available and to the biological signals they receive. Studies on joint health reported beneficial outcomes including pain reduction, improvements in clinical parameters, increased physical mobility, and enhanced function from hydrolysed collagen supplementation.
Bone
This is where the menopause-collagen connection is least well known but perhaps most consequential. Bone is commonly understood as a mineral structure, but it is 20 to 25% collagen by dry weight. The collagen matrix of bone, composed primarily of Type I collagen, provides the flexible scaffolding into which calcium and minerals are incorporated. Without an intact collagen matrix, bone becomes brittle rather than strong — a distinction that bone mineral density scans alone do not fully capture.
In a 2018 RCT of postmenopausal women with low bone density, those taking collagen peptides had increased bone mineral density after 12 months compared to placebo.
A clinical trial involving 51 postmenopausal women with pre-osteoporosis found that 5g of collagen per day for 3 months brought about improvements in the marker CTX, which links with declining levels of bone collagen and increased fracture risk. A decrease in CTX indicates improving bone health.
Important caveat: studies focused on bone health faced limitations that prevent definitive conclusions about the effects of collagen supplementation. The direction of evidence is encouraging and biologically plausible, but this area requires more large-scale, long-term research before firm clinical recommendations can be made.
The case for a multi-peptide approach during menopause
The reason the menopause transition is such a significant period for collagen supplementation is precisely that multiple tissue systems are affected simultaneously. It is not a skin problem or a bone problem or a joint problem. It is a whole-body connective tissue event driven by a single hormonal shift.
This is why a product that combines multiple tissue-specific peptides in a single daily serving makes particular clinical sense for women going through this transition. NDS Multi Collagen Total combines CPV 101 for skin, hair and nails, CPF 218 for joint cartilage, and CPFB 105 for bone matrix — three peptides targeting three different cell types in one tasteless daily scoop.
For women over 55, NDS Multi Collagen 55+ addresses joint cartilage, bone matrix and muscle connective tissue — the priorities that tend to be most clinically significant in the post-menopausal years as the initial rapid decline plateaus into the slower 2.1% annual rate.
What collagen supplementation cannot do
Collagen supplementation during menopause is nutritional support, not hormone replacement. It does not replace oestrogen's role in collagen synthesis regulation, and it will not reverse the fundamental hormonal changes of the menopause transition. Women who are considering HRT for menopausal symptoms should discuss this with their GP or menopause specialist — that is a clinical decision that sits outside the scope of nutritional support.
What collagen supplementation can do is provide the substrate and cellular signalling that supports the tissues trying to maintain themselves in an environment of reduced oestrogen. It works downstream of the hormonal change rather than addressing it at its source. That is a meaningful and clinically useful contribution, but it is important to understand what it is and what it is not.
Practical considerations for menopause and collagen
When to start. Perimenopause, the transitional period before periods stop, is the point at which oestrogen begins to fluctuate and collagen decline begins to accelerate. Starting collagen support during perimenopause rather than waiting until post-menopause means beginning before the most rapid phase of loss, which is clinically more sensible than starting reactively.
Dose and duration. The clinical studies that have shown meaningful outcomes in postmenopausal women consistently use 5g of specific collagen peptides daily over a minimum of 8 to 12 weeks. Collagen supplementation is cumulative, not acute. Consistent daily use over months is the basis on which the evidence is built.
Vitamin C. Vitamin C is a required cofactor in collagen synthesis. It is involved in the hydroxylation of proline and lysine, the step that stabilises the collagen triple helix. Ensuring adequate vitamin C intake alongside collagen supplementation supports the body's own synthesis pathways alongside the external peptide input.
Protein intake. Muscle mass declines alongside collagen during menopause. Adequate overall protein intake supports both muscle protein synthesis and the amino acid pool from which collagen is built. Women in perimenopause and post-menopause often benefit from a deliberate increase in dietary protein alongside targeted collagen peptide supplementation.
Weight-bearing exercise. The delivery of nutrients to cartilage depends on mechanical joint loading. The maintenance of bone density is supported by weight-bearing and resistance exercise. Regular physical activity is not just complementary to collagen supplementation during menopause — it enhances the delivery mechanism and provides its own independent structural stimulus.
Frequently asked questions
Is collagen supplementation suitable alongside HRT?
There are no known interactions between collagen peptide supplementation and hormone replacement therapy. The two work through different mechanisms and can be used alongside each other. HRT addresses the hormonal cause of accelerated collagen decline. Collagen peptides provide substrate and signalling support to the tissues undergoing that decline. If you are taking any prescribed medication or therapy, discussing any new supplement with your prescribing doctor is always a reasonable step.
How long before I would notice any difference?
Based on the RCTs conducted in postmenopausal women, the most commonly reported timeframe for noticeable changes in skin is 8 to 12 weeks of consistent daily use. Joint changes typically take longer, with most studies using 12 to 24 weeks as their endpoint. Bone changes are the slowest to manifest and require the longest study periods to detect. The honest answer is that collagen supplementation requires patience and consistency to evaluate properly.
Which NDS product is most appropriate for menopause?
It depends on which symptoms are most significant for you. For skin and hair as the primary concern, NDS Collagen SkinActive with CPV 101 is the most targeted option. For joint stiffness and cartilage support, NDS Collagen Ezy Move with CPF 218. For bone support, NDS Collagen BoneX with CPFB 105. For comprehensive support across all three systems in one serving, NDS Multi Collagen Total combines all three peptides. Women over 55 with a focus on joints, bone and muscle may find NDS Multi Collagen 55+ most appropriate.
Does it matter which type of collagen I take?
Yes, significantly. The peptide type and molecular weight determine which tissue benefits. A generic collagen product that does not specify the peptide fraction, its molecular weight, or its target tissue is not making a clinically meaningful claim. The studies that show benefit in postmenopausal women use specific bioactive collagen peptides at defined doses, not generic collagen protein. This is the distinction that NDS formulations are built around.
Is the collagen in supplements the same as the collagen lost during menopause?
Not directly. Collagen peptides taken orally are hydrolysed fragments, not intact collagen molecules. They are absorbed into the bloodstream and travel to target tissues where they act in two ways: a portion binds to receptors in collagen-producing cells and signals them to increase their own synthesis activity, while the remainder is broken down into the amino acids used as building material. So the supplement does not replace the lost collagen molecule for molecule. It supports the body's own production system and supplies the raw materials it needs to rebuild.
NDS Nutrition offers a full range of tissue-specific collagen peptides, from targeted single-peptide products to comprehensive multi-peptide formulations. All products are practitioner-formulated, tasteless and water-soluble, with 98.4% documented digestibility.
Explore the NDS Collagen Range →Sources: Viscomi et al. (2025) Journal of Cosmetic Dermatology; Duangjai et al. (2025) Clinical Practice RCT on menopausal women; Coastal Private GP & Aesthetics collagen and menopause evidence review (2026); ScienceDirect skin collagen and bone mass study; MenoHello collagen and menopause impact analysis; Kollo Health collagen menopause research summary; Oesser S. (2020) NDS HairActive peer-reviewed RCT; Systematic review of 36 RCTs on Type I hydrolysed collagen, Orthopedic Reviews (2025); Lydeking E. (2020) NDS Collagen clinical white paper.